Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A.R.R.O.W.2: Once-weekly vs twice-weekly carfilzomib with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma
NL-OMON52761Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carfilzomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Amgen. Primary endpoint: Overall response. Started Sep 2019; status: active, not recruiting.
02
Drugs
carfilzomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON52761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52761.